CSIMarket
 
Akorn Inc  (AKRXQ)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 133
 Employees 2,040
 Revenues (TTM) (Millions $) 664
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -95
 Capital Exp. (TTM) (Millions $) 33

Akorn Inc
due to regulatory issues, the acquisition was terminated in 2018. Despite numerous legal battles, Akorn has continued to grow its business and expand its portfolio.

In terms of manufacturing capacity, Akorn has numerous state-of-the-art facilities located in the United States, China, India, and Switzerland. Its production facilities are compliant with the strictest quality and safety standards set by various international regulatory bodies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO).

Akorn has also established a strong global distribution network, partnering with leading distributors and wholesalers to ensure timely delivery of its products to customers and patients worldwide. The company has a dedicated team of professionals who are committed to providing high-quality products, outstanding customer service, and delivering effective medical solutions to address the evolving needs of the market.

Overall, Akorn is a leading global pharmaceutical company with a strong brand name, diverse product portfolio, state-of-the-art manufacturing facilities, and a robust global distribution network. The company remains committed to delivering innovative, high-quality, and cost-effective healthcare solutions to healthcare professionals, patients, and the animal health industry worldwide.


   Company Address: 1925 W. Field Court, Lake Forest, 60045 IL
   Company Phone Number: 279-6100   Stock Exchange / Ticker: AKRXQ
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Neurogene Inc. Breaks Ground in Rare Neurological Disorder Research with Expansion of NGN-401 Trial

Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment.
Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.

Eyenovia Inc

The Major Pharmaceutical Preparations company released Revenue of $0.002589 million, in thefourth quarter of 2023 financial report

EYEN proclaimed $0.002589 million, in Revenue in the October to December 31 2023 fiscal time-frame.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Following the leaders in the Major Pharmaceutical Preparations industry, some lesser known companies are publishing the numbers. ATXI told it has clinched operating loss of $-2.12 million, for the fourth quarter of 2023.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 

Akorn Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com